Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Phase 3 crawled date : 2022 - 05 - 23 save search
AbbVie Presents Positive Data from Phase 3 Study of Cariprazine (VRAYLAR®) for the Adjunctive Treatment of Major Depressive Disorder at 2022 APA Annual Meeting
Published: 2022-05-23 (Crawled : 16:00) - biospace.com/
ABBV | News | $170.19 1.37% 1.6M
|
Health Technology
|
| O: -0.51%
H: 0.0%
C: 0.0%
vraylar treatment positive phase 3 major depressive disorder
Positive Results from VISEN’s Phase 3 Trial of Once-Weekly TransCon hGH in China Consistent with Ascendis Pharma’s Phase 3 Height Trial
Published: 2022-05-23 (Crawled : 15:00) - biospace.com/
ASND | $146.045 2.78% 61K
|
Health Technology
|
| O: 4.07%
H: 2.7%
C: 1.55%
trial china positive results phase 3
Alnylam Presents New 18-Month Results from Exploratory Cardiac Endpoints in HELIOS-A Phase 3 Study of Investigational Vutrisiran
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
ALNY | $148.99 2.2% 130K
|
Health Technology
|
| O: 2.06%
H: 0.0%
C: 0.0%
cardiac results phase 3
Concert Pharmaceuticals Reports Positive Topline Results for First CTP-543 Phase 3 Clinical Trial in Alopecia Areata
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
CNCE | $8.37 0.36% 0
|
Health Technology
|
| O: 6.07%
H: 8.26%
C: -13.24%
ctp-543 topline trial positive phase 3
Biohaven Provides Update on Phase 3 Clinical Trial Evaluating Troriluzole for Spinocerebellar Ataxia (SCA)
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
BHVN | News 0 d | $39.92 4.15% 1.3M
|
Health Technology
|
| O: 0.25%
H: 1.91%
C: 0.92%
trial phase 3
PolyPid Announces Recommendation by Data Safety Monitoring Board to Conclude Enrollment of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ at the Minimum Number of Patients Targeted Following Unblinded Interim Efficacy Analysis
Published: 2022-05-23 (Crawled : 12:00) - biospace.com/
PYPD | $4.425 35
|
Health Technology
|
| O: 2.54%
H: 4.77%
C: -3.24%
trial enroll phase 3
VISEN Pharmaceuticals Announces Top-line Results of Phase 3 Trial of Once-Weekly Lonapegsomatropin, Demonstrating Superior Efficacy, Comparable Safety and Tolerability to Daily Growth Hormone
Published: 2022-05-23 (Crawled : 08:00) - prnewswire.com
ASND | $146.045 2.78% 61K
|
Health Technology
|
| O: 4.07%
H: 2.7%
C: 1.55%
trial results growth hormone phase 3 topline
Positive Phase 3 study with aprocitentan demonstrates significant antihypertensive efficacy in patients with resistant hypertension
Published: 2022-05-23 (Crawled : 06:00) - globenewswire.com
JNJ | News | $149.575 0.31% 2.5M
|
Health Technology
|
| O: 1.57%
H: 0.0%
C: 0.0%
hypertension positive phase 3
Gainers vs Losers
| 87% | 13% |
Top 10 Gainers
MTTR | News M | $4.595 164.08% 13M
|
AGBA | $2.61 108.8% 41M
|
Finance
CZOO | $9.32 86.77% 18M
|
EDBL | News | $6.7 78.19% 1.7M
|
MTC | $2.28 46.15% 2.6M
|
Technology Services
OPRT | News | $3.14 39.56% 7.6M
|
Finance
VNRX | $0.8 33.33% 2.9M
|
Health Technology
MLEC | $1.865 33.21% 2.4M
|
n/a
PALI | $6.37 29.21% 21M
|
Manufacturing
LOCL | $3.33 27.59% 43K
|
Your saved searches
Save your searches and get alerts when important news are released.